Evidence map›Paper›PMID 28362102›Full record

ArticleChemical research in toxicology2017

Systems Toxicology: Real World Applications and Opportunities.

Thomas Hartung, Rex E FitzGerald, Paul Jennings, Gary R Mirams, Manuel C Peitsch, Amin Rostami-Hodjegan, Imran Shah, Martin F Wilks, Shana J Sturla

Abstract read
In one paragraph

Article in Chemical research in toxicology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed.

  1. Review
  2. Review
  3. Unveiling toxicological adverse outcomes: toward construction and simulation of large-scale networks.Toxicological sciences : an official journal of the Society of Toxicology · 2026
    Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Characterization of primary canine Sertoli cells as a model to test male reproductive toxicant.Toxicology in vitro : an international journal published in association with BIBRA · 2022
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Thomas HartungCenter for Alternatives to Animal Testing (CAAT), Johns Hopkins Bloomberg School of Public Health , Baltimore, Maryland 21205, United States.ORCID 0000-0003-1359-7689
Rex E FitzGeraldSwiss Centre for Applied Human Toxicology, University of Basel , 4055 Basel, Switzerland.
Paul JenningsDivision of Physiology, Department of Physiology and Medical Physics, Medical University of Innsbruck , 6020 Innsbruck, Austria.
Gary R MiramsCentre for Mathematical Medicine & Biology, School of Mathematical Sciences, University of Nottingham , Nottingham NG7 2RD, U.K.
Manuel C PeitschDepartment of Research and Development, Philip Morris International , 2000 Neuchâtel, Switzerland.
Amin Rostami-HodjeganCentre for Applied Pharmacokinetic Research, University of Manchester , Manchester M13 9PL, U.K.
Imran ShahNational Center for Computational Toxicology , Research Triangle Park, North Carolina 27711, United States.
Martin F WilksSwiss Centre for Applied Human Toxicology, University of Basel , 4055 Basel, Switzerland.
Shana J SturlaDepartment of Health Sciences and Technology, ETH Zurich , 8092 Zurich, Switzerland.ORCID 0000-0001-6808-5950

Funding

Mapping the Human Toxome by Systems ToxicologyR01ES020750 · NIEHS · JOHNS HOPKINS UNIVERSITY · PI HARTUNG, THOMAS · 2011 to 2015
$6.0M
European Research Council 680920NIEHS NIH HHS R01 ES020750Wellcome Trust 101222/Z/13/Z
6 · The paper itself

Abstract

Systems Toxicology aims to change the basis of how adverse biological effects of xenobiotics are characterized from empirical end points to describing modes of action as adverse outcome pathways and perturbed networks. Toward this aim, Systems Toxicology entails the integration of in vitro and in vivo toxicity data with computational modeling. This evolving approach depends critically on data reliability and relevance, which in turn depends on the quality of experimental models and bioanalysis techniques used to generate toxicological data. Systems Toxicology involves the use of large-scale data streams ("big data"), such as those derived from omics measurements that require computational means for obtaining informative results. Thus, integrative analysis of multiple molecular measurements, particularly acquired by omics strategies, is a key approach in Systems Toxicology. In recent years, there have been significant advances centered on in vitro test systems and bioanalytical strategies, yet a frontier challenge concerns linking observed network perturbations to phenotypes, which will require understanding pathways and networks that give rise to adverse responses. This summary perspective from a 2016 Systems Toxicology meeting, an international conference held in the Alps of Switzerland, describes the limitations and opportunities of selected emerging applications in this rapidly advancing field. Systems Toxicology aims to change the basis of how adverse biological effects of xenobiotics are characterized, from empirical end points to pathways of toxicity. This requires the integration of in vitro and in vivo data with computational modeling. Test systems and bioanalytical technologies have made significant advances, but ensuring data reliability and relevance is an ongoing concern. The major challenge facing the new pathway approach is determining how to link observed network perturbations to phenotypic toxicity.

Indexed as

Models, TheoreticalHalf-LifeHeartHigh-Throughput Screening AssaysHumansKidneyLiverMetabolomicsProteomicsXenobioticsXenobiotics

Identifiers

PMID28362102
PMCPMC5396025

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.